Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts

K. Sakhaee, M. Nicar, K. Hill, C. Y C Pak

Research output: Contribution to journalArticle

179 Citations (Scopus)

Abstract

Effects of potassium citrate therapy (60 mEq/day) on urinary chemistries and crystallization were compared to those of sodium citrate treatments in five patients with uric acid lithiasis. Both alkali treatments significantly increased urinary pH (P < 0.001), from 5.35 ± 0.18 SD to 6.68 ± 0.14 for potassium citrate and 6.73 ± 0.20 for sodium citrate. During potassium citrate therapy, urinary calcium significantly declined from 154 ± 47 mg/day to 99 ± 23 mg/day (P < 0.01) and urinary citrate rose from 398 ± 119 mg/day to 856 ± 103 mg/day (P < 0.001). The urinary saturation (activity product ratio) of calcium oxalate decreased from 3.21-fold to 1.69-fold saturation (P < 0.01), and the inhibitor activity against calcium oxalate precipitation (formation product ratio) significantly increased. However, sodium citrate therapy did not significantly decrease urinary calcium (to 139 ± 24 mg/day), although it increased urinary citrate substantially (to 799 ± 89 mg/day, P < 0.01). Urinary environment became supersaturated with respect to brushite (calcium phosphate) and monosodium urate. The inhibitor activity against calcium oxalate precipitation was not significantly altered for the whole group; in two patients, it decreased by more than 30%. The results indicate that (1) both alkali therapies are equally effective in preventing uric acid stone formation because of their ability to increase urinary pH, and (2) potassium citrate may prevent the complication of calcium nephrolithiasis in patients with uric acid stones, whereas sodium citrate may not.

Original languageEnglish (US)
Pages (from-to)348-352
Number of pages5
JournalKidney International
Volume24
Issue number3
StatePublished - 1983

Fingerprint

Potassium Citrate
Crystallization
Salts
Uric Acid
Calcium Oxalate
Alkalies
Calcium
Citric Acid
Therapeutics
Nephrolithiasis
Lithiasis
sodium citrate

ASJC Scopus subject areas

  • Nephrology

Cite this

@article{6d9df145f42e4c1381a51b243ff2290a,
title = "Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts",
abstract = "Effects of potassium citrate therapy (60 mEq/day) on urinary chemistries and crystallization were compared to those of sodium citrate treatments in five patients with uric acid lithiasis. Both alkali treatments significantly increased urinary pH (P < 0.001), from 5.35 ± 0.18 SD to 6.68 ± 0.14 for potassium citrate and 6.73 ± 0.20 for sodium citrate. During potassium citrate therapy, urinary calcium significantly declined from 154 ± 47 mg/day to 99 ± 23 mg/day (P < 0.01) and urinary citrate rose from 398 ± 119 mg/day to 856 ± 103 mg/day (P < 0.001). The urinary saturation (activity product ratio) of calcium oxalate decreased from 3.21-fold to 1.69-fold saturation (P < 0.01), and the inhibitor activity against calcium oxalate precipitation (formation product ratio) significantly increased. However, sodium citrate therapy did not significantly decrease urinary calcium (to 139 ± 24 mg/day), although it increased urinary citrate substantially (to 799 ± 89 mg/day, P < 0.01). Urinary environment became supersaturated with respect to brushite (calcium phosphate) and monosodium urate. The inhibitor activity against calcium oxalate precipitation was not significantly altered for the whole group; in two patients, it decreased by more than 30{\%}. The results indicate that (1) both alkali therapies are equally effective in preventing uric acid stone formation because of their ability to increase urinary pH, and (2) potassium citrate may prevent the complication of calcium nephrolithiasis in patients with uric acid stones, whereas sodium citrate may not.",
author = "K. Sakhaee and M. Nicar and K. Hill and Pak, {C. Y C}",
year = "1983",
language = "English (US)",
volume = "24",
pages = "348--352",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts

AU - Sakhaee, K.

AU - Nicar, M.

AU - Hill, K.

AU - Pak, C. Y C

PY - 1983

Y1 - 1983

N2 - Effects of potassium citrate therapy (60 mEq/day) on urinary chemistries and crystallization were compared to those of sodium citrate treatments in five patients with uric acid lithiasis. Both alkali treatments significantly increased urinary pH (P < 0.001), from 5.35 ± 0.18 SD to 6.68 ± 0.14 for potassium citrate and 6.73 ± 0.20 for sodium citrate. During potassium citrate therapy, urinary calcium significantly declined from 154 ± 47 mg/day to 99 ± 23 mg/day (P < 0.01) and urinary citrate rose from 398 ± 119 mg/day to 856 ± 103 mg/day (P < 0.001). The urinary saturation (activity product ratio) of calcium oxalate decreased from 3.21-fold to 1.69-fold saturation (P < 0.01), and the inhibitor activity against calcium oxalate precipitation (formation product ratio) significantly increased. However, sodium citrate therapy did not significantly decrease urinary calcium (to 139 ± 24 mg/day), although it increased urinary citrate substantially (to 799 ± 89 mg/day, P < 0.01). Urinary environment became supersaturated with respect to brushite (calcium phosphate) and monosodium urate. The inhibitor activity against calcium oxalate precipitation was not significantly altered for the whole group; in two patients, it decreased by more than 30%. The results indicate that (1) both alkali therapies are equally effective in preventing uric acid stone formation because of their ability to increase urinary pH, and (2) potassium citrate may prevent the complication of calcium nephrolithiasis in patients with uric acid stones, whereas sodium citrate may not.

AB - Effects of potassium citrate therapy (60 mEq/day) on urinary chemistries and crystallization were compared to those of sodium citrate treatments in five patients with uric acid lithiasis. Both alkali treatments significantly increased urinary pH (P < 0.001), from 5.35 ± 0.18 SD to 6.68 ± 0.14 for potassium citrate and 6.73 ± 0.20 for sodium citrate. During potassium citrate therapy, urinary calcium significantly declined from 154 ± 47 mg/day to 99 ± 23 mg/day (P < 0.01) and urinary citrate rose from 398 ± 119 mg/day to 856 ± 103 mg/day (P < 0.001). The urinary saturation (activity product ratio) of calcium oxalate decreased from 3.21-fold to 1.69-fold saturation (P < 0.01), and the inhibitor activity against calcium oxalate precipitation (formation product ratio) significantly increased. However, sodium citrate therapy did not significantly decrease urinary calcium (to 139 ± 24 mg/day), although it increased urinary citrate substantially (to 799 ± 89 mg/day, P < 0.01). Urinary environment became supersaturated with respect to brushite (calcium phosphate) and monosodium urate. The inhibitor activity against calcium oxalate precipitation was not significantly altered for the whole group; in two patients, it decreased by more than 30%. The results indicate that (1) both alkali therapies are equally effective in preventing uric acid stone formation because of their ability to increase urinary pH, and (2) potassium citrate may prevent the complication of calcium nephrolithiasis in patients with uric acid stones, whereas sodium citrate may not.

UR - http://www.scopus.com/inward/record.url?scp=0020528698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020528698&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 348

EP - 352

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 3

ER -